The breadth of BPC-157s preclinical profile spanning gastrointestinal protection, musculoskeletal repair, angiogenesis, neuroprotection, and cytoprotection has sustained interest from research groups investigating tissue repair mechanisms and regenerative biology
Systemic Inflammation and Post-Injury Recovery For patients with widespread musculoskeletal inflammation, chronic soft tissue pain, or a recent surgical recovery, BPC-157 is most often prescribed as part of the Wolverine Stack, which combines BPC-157 with TB-500 (Thymosin Beta-4) for synergistic tissue repair
hospitalization required Maintenance of Remission: Immunomodulators (azathioprine, 6-MP, methotrexate) for steroid-dependent or frequently-relapsing disease Biologic monotherapy or combination therapy (biologic + immunomodulator) for moderate-to-severe disease Step-up or top-down approach based on disease severity, patient risk factors, and prior therapy Biologic Therapy Targets: TNF-: Infliximab (IV), adalimumab (SC), certolizumab pegol (SC) IL-12/23: Ustekinumab (IV induction, SC maintenance) Integrin: Vedolizumab (IV) IL-23: Risankizumab (IV induction, SC maintenance) JAK inhibition: Upadacitinib (oral) Surgical Management Surgery is indicated in approximately 7080% of patients with Crohns disease over their lifetime, per StatPearls
Addy, Patient Coordinator Addy welcomes patients at the front desk and handles scheduling, check-in, and the walk-in flow
